|
Quality of Life
Citations 1-10 of 20 total displayed.
|
Most recent content
(1 Oct 2006):
|
- Original Contributions
High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis
- Douglas E. Gladstone; Kenneth W. Zamkoff; Lauren Krupp; Robert Peyster; Patrick Sibony; Christopher Christodoulou; Emily Locher; Patricia K. Coyle
Arch Neurol 2006; 63: 1388-1393.
[Abstract]
[Full text]
[PDF]
|
Past content
(since May 1998):
|
- Original Contributions
High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis
- Douglas E. Gladstone; Kenneth W. Zamkoff; Lauren Krupp; Robert Peyster; Patrick Sibony; Christopher Christodoulou; Emily Locher; Patricia K. Coyle
Arch Neurol 63.10.noc60076.
[Abstract]
[Full text]
[PDF]
- Original Contributions
Subthalamic Stimulation in Parkinson Disease: Behavior and Social Adaptation
- Jean-Luc Houeto; Luc Mallet; Valérie Mesnage; Sophie Tezenas du Montcel; Cécile Béhar; Marcela Gargiulo; Frederic Torny; Antoine Pelissolo; Marie-Laure Welter; Yves Agid
Arch Neurol 2006; 63: 1090-1095.
[Abstract]
[Full text]
[PDF]
- Original Contributions
Effects of Ultra–Low-Dose Transdermal Estradiol on Cognition and Health-Related Quality of Life
- Kristine Yaffe; Eric Vittinghoff; Kristine E. Ensrud; Karen C. Johnson; Susan Diem; Vladimir Hanes; Deborah Grady
Arch Neurol 2006; 63: 945-950.
[Abstract]
[Full text]
[PDF]
- Correspondence
Quality of Life Is Not Favorable for Most Patients With Multiple Sclerosis
- Alex J. Mitchell; Julían Benito-León; Jesús Rivera-Navarro; José Manuel Morales-González
Arch Neurol 2004; 61: 1807-a-1808-a.
[Extract]
[Full text]
[PDF]
- Correspondence
Adaptation Is Favorable for Most Patients With Multiple Sclerosis
- A. Cecile J. W. Janssens; Rogier Q. Hintzen
Arch Neurol 2004; 61: 1807.
[Extract]
[Full text]
[PDF]
- Correspondence
Quality of Life Is Not Favorable for Most Patients With Multiple Sclerosis—Reply
- Sean J. Pittock; Robyn L. McClelland; Moses Rodriguez
Arch Neurol 2004; 61: 1808.
[Extract]
[Full text]
[PDF]
- Correspondence
Disease Course of Charcot-Marie-Tooth Disease Type 2 and Comorbidity—Reply
- Laurien L. Teunissen; Nicolette C. Notermans; Hessel Franssen; Baziel G. M. van Engelen; Frank Baas; John H. J. Wokke
Arch Neurol 2004; 61: 1470-a.
[Extract]
[Full text]
[PDF]
- Correspondence
Disease Course of Charcot-Marie-Tooth Disease Type 2 and Comorbidity
- Franco Gemignani; Adriana Marbini
Arch Neurol 2004; 61: 1470.
[Extract]
[Full text]
[PDF]
- Original Contributions
Effectiveness, Tolerability, and Impact on Quality of Life of the 5% Lidocaine Patch in Diabetic Polyneuropathy
- Richard L. Barbano; David N. Herrmann; Stephanie Hart-Gouleau; Janet Pennella-Vaughan; Peter A. Lodewick; Robert H. Dworkin
Arch Neurol 2004; 61: 914-918.
[Abstract]
[Full text]
[PDF]
|
|
